DermaRite Expands Recall of 32 Personal Care Products Over Bacteria Risk

Lead DermaRite Industries has expanded its voluntary recall to 32 soaps, lotions, shampoos and sanitizers nationwide today, citing contamination with Burkholderia cepacia complex that poses serious infection risks.

Nut Graf Out of an abundance of caution, the New Jersey-based manufacturer warned that its expanded recall affects a broad range of healthcare and retail products distributed across the U.S. and Puerto Rico, urging consumers-especially immunocompromised individuals-to stop use and consult a healthcare provider immediately.

Recall Details

  • Products affected include 3-N-1 body wash, 4-N-1 wash cream, Clean-N-Free body wash and shampoo, DermaCerin moisturizing cream, DermaDaily lotion, DermaFungal antifungal cream, DermaKleen antiseptic soap, DermaMed skin protectant, DermaRain shampoo, DermaSyn wound dressing, DermaVantage lotion, DermaVera cleanser, Gel Rite hand sanitizer, Hand E Foam sanitizer, KleenFoam foam soap, Lantisep skin protectant, PeriFresh cleanser, PeriGuard protectant, Renew Skin Repair cream, Renew Periprotect, Renew Dimethicone, UltraSure antiperspirant, and several others.
  • All recalled items carry expiration dates from July 2025 through August 2027.
  • Distribution channels span healthcare facilities, online retailers (Amazon, Target, Walmart) and other outlets nationwide, including Puerto Rico.

Health Risks

  • Burkholderia cepacia complex can survive in aqueous solutions and cause severe, sometimes life-threatening infections in immunocompromised patients.
  • Healthy users with minor skin lesions risk localized infections; immunosuppressed individuals face potential bloodstream sepsis.
  • The bacterium’s resistance to multiple antibiotics heightens treatment challenges.

Company Statement and Consumer Guidance

  • DermaRite emphasized its commitment to transparency and patient safety, noting wound care and nutritional products remain unaffected.
  • Consumers should halt use of recalled items, destroy them according to facility or household protocols, and report adverse events to FDA MedWatch.
  • For inquiries, contact Sedgwick at 888-943-5190 (Mon-Fri, 8 am-5 pm EST) or email [email protected].